The Copenhagen SARS-CoV-2 antibody initiative

Molecular testing of SARS-CoV-2 identifies individuals that are currently infected with the virus. Anti-SARS-CoV-2 antibody testing identifies previously infected individuals. Our group at Rigshospitalet and University of Copenhagen in collaboration with Novo Nordisk A/S has developed different antibody assays to monitor the immune response against SARS-CoV-2. We now want to perform an in-depth investigation of which SARS-CoV-2 antigens the immune response is directed against. Additionally, we want to investigate what types of antibodies that are generated during the infection, including their affinity and avidity and whether the antibodies indeed are protective or not. This type of knowledge will enable a better understanding of the duration of a SARS-Cov-2 antibody response and if the antibodies provide immunity against the virus. This information can also help the authorities to understand how widespread the SAR-Cov-2 infection is in the society and could help support the development of new treatment and vaccine strategies against COVID-19. https://sciencenews.dk/en/new-covid-19-antibody-test-should-tell-us-how-we-become-immune